An updated blood test detected 18.2% of advanced precancerous growths, versus 13.7% in the earlier study.
Freenome (FRNM) announced improved performance in its updated SimpleScreen CRC blood test, detecting 18.2% of advanced precancerous lesions compared to 13.7% in the earlier study. The test was FDA-approved in July 2026 and commercially launched in September. Results will be presented at the ACG 2026 Annual Meeting.
How this was made
The 30-second read
Why it matters
The data could accelerate commercial rollout and attract partnership or acquisition interest.
Market read
First disclosure of pivotal trial data for a listed biotech, likely to move FRNM and related sector stocks.
What to watch
Reimbursement decisions and competition from other liquid biopsy firms could limit upside.
Background
Freenome's SimpleScreen CRC received FDA approval earlier this year and launched with Abbott; the updated version shows improved sensitivity.
Ticker impact
Freenome announced updated SimpleScreen CRC blood test shows higher detection of advanced precancerous lesions, a first report of pivotal trial data.
upward pressure as the market prices in higher sensitivity and potential market adoption.
New clinical validation data for a listed biotech is material and often moves the stock on the day of release.
Market effects
May boost the broader early cancer detection and liquid biopsy sector.
US biotech market could see increased investor interest.
Potentially influences global multiomics and diagnostic technology investors.
Counterpoint
If the test fails to achieve commercial uptake, the hype may be short-lived.
Key entities
- CompanyFreenome, Inc.
Early cancer detection biotech listed on Nasdaq (FRNM).
- CompanyAbbott Cancer Diagnostics
Partner commercializing the test.
